GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reneo Pharmaceuticals Inc (NAS:RPHM) » Definitions » Cash-to-Debt

Reneo Pharmaceuticals (Reneo Pharmaceuticals) Cash-to-Debt : 91.33 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reneo Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Reneo Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 91.33.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Reneo Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Reneo Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

RPHM' s Cash-to-Debt Range Over the Past 10 Years
Min: 69.15   Med: 110.48   Max: No Debt
Current: 91.33

During the past 5 years, Reneo Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 69.15. And the median was 110.48.

RPHM's Cash-to-Debt is ranked better than
78.22% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs RPHM: 91.33

Reneo Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Reneo Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Reneo Pharmaceuticals Cash-to-Debt Chart

Reneo Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
No Debt No Debt No Debt 69.15 105.82

Reneo Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.89 117.43 110.48 105.82 91.33

Competitive Comparison of Reneo Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Reneo Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reneo Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reneo Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Reneo Pharmaceuticals's Cash-to-Debt falls into.



Reneo Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Reneo Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Reneo Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reneo Pharmaceuticals  (NAS:RPHM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Reneo Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Reneo Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Reneo Pharmaceuticals (Reneo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
18575 Jamboree Road, Suite 275-S, Irvine, CA, USA, 92612
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
Executives
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
Michael Cruse officer: Senior VP, Corporate Operation C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jennifer Lam officer: VP of Finance & Administration C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S, IRVINE CA 92612
Paul W. Hoelscher director 1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Vineet R. Jindal officer: Chief Financial Officer C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Gregory J. Flesher director, officer: President and CEO 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077
Wendy S. Johnson officer: Chief Development Officer 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Rivervest Venture Fund Iii (ohio), L.p. 10 percent owner 11000 CEDAR AVENUE, SUITE 100, CLEVELAND OH 44106-3502
Rivervest Venture Fund Iii, L.p. 10 percent owner 7733 FORSYTH BOULEVARD, ST. LOUIS MO 63105
Stacey Denenberg Seltzer director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106